Axon Enterprise, Inc.
$39.59B- Market cap
- $38.90B
- Debt
- +$1.89B
- Cash
- −$1.20B
Capital structure 95% equity / 5% debt · EV / Revenue 14.24x · EV proxy / EBITDA proxy 1877.67x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 ·
Decision snapshot: AXON stock price at premium vs JNJ $478.85 current versus $36.46 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at JNJ's multiple
Implied fair value · at AXON's multiple
Snapshot Sep 10, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Multiple premium
Higher P/E
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Capital structure 95% equity / 5% debt · EV / Revenue 14.24x · EV proxy / EBITDA proxy 1877.67x
Capital structure 93% equity / 7% debt · EV / Revenue 7.11x
JNJ carries the larger enterprise value at $670.11B against $39.59B; JNJ trades on the lower EV / Revenue multiple (7.11x vs 14.24x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Axon Enterprise, Inc. · implied price per share
Bear
$23.07
Base
$28.02
Bull
$34.69
Johnson & Johnson · implied price per share
Bear
$93.96
Base
$115.89
Bull
$146.14
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
TYLER TECHNOLOGIES INC
AXON vs TYL
TELEDYNE TECHNOLOGIES INC
AXON vs TDY
LOCKHEED MARTIN CORP
AXON vs LMT
GENERAL DYNAMICS CORP
AXON vs GD
HUNTINGTON INGALLS INDUSTRIES, INC.
AXON vs HII
Howmet Aerospace Inc.
AXON vs HWM
Pfizer Inc.
AXON vs PFE
Eli Lilly and Company
AXON vs LLY
Abbott Laboratories
AXON vs ABT
Amgen Inc.
AXON vs AMGN
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.